Structure Therapeutics American Stock Today
| GPCR Stock | 20.34 0.71 3.37% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Structure Therapeutics is selling at 20.34 as of the 26th of March 2025; that is 3.37 percent down since the beginning of the trading day. The stock's lowest day price was 20.1. Structure Therapeutics has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Note, on November 1, 2023, Senator Thomas R Carper of US Senate acquired under $15k worth of Structure Therapeutics's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2023 | Category Healthcare | Classification Health Care |
Structure Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 57.34 M outstanding shares of which 6.61 M shares are currently shorted by private and institutional investors with about 8.29 trading days to cover. More on Structure Therapeutics American
Moving together with Structure Stock
Moving against Structure Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Structure Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Raymond Stevens | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Structure Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Structure Therapeutics' financial leverage. It provides some insight into what part of Structure Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Structure Therapeutics American (GPCR) is traded on NASDAQ Exchange in USA. It is located in 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 163 people. Structure Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.21 B. Structure Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 57.34 M outstanding shares of which 6.61 M shares are currently shorted by private and institutional investors with about 8.29 trading days to cover.
Structure Therapeutics generates negative cash flow from operations
Check Structure Therapeutics Probability Of Bankruptcy
Ownership AllocationStructure Therapeutics shows a total of 57.34 Million outstanding shares. The majority of Structure Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Structure Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Structure Therapeutics. Please pay attention to any change in the institutional holdings of Structure Therapeutics American as this could imply that something significant has changed or is about to change at the company. Also note that roughly one hundred sixty-six thousand two hundred ninety-four invesors are currently shorting Structure Therapeutics expressing very little confidence in its future performance.
Check Structure Ownership Details
Structure Therapeutics Historical Income Statement
Structure Stock Against Markets
Structure Therapeutics Corporate Management
| Lani Ibarra | Senior Operations | Profile | |
| Hui Lei | Senior Chemistry | Profile | |
| Xichen Lin | Chief Officer | Profile | |
| Yingli Ma | Chief Officer | Profile | |
| Fang Zhang | Executive Biology | Profile |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.